PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
0.06 - 0.06
0.06 - 0.24
8.7K / 3.59M (Avg.)
-1.55 | -0.04
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
Negative 10Y revenue/share CAGR while CRN.AX stands at 0.00%. Joel Greenblatt would question if the company is failing to keep pace with industry changes.
-100.00%
Negative 5Y CAGR while CRN.AX stands at 0.00%. Joel Greenblatt would push for a turnaround plan or reevaluation of the company’s product line.
No Data
No Data available this quarter, please select a different quarter.
53.90%
OCF/share CAGR of 53.90% while CRN.AX is zero. Bruce Berkowitz might see a slight advantage that could compound over time.
53.90%
OCF/share CAGR of 53.90% while CRN.AX is zero. Bruce Berkowitz would see if modest momentum can translate into a bigger competitive lead.
56.60%
3Y OCF/share CAGR of 56.60% while CRN.AX is zero. Bruce Berkowitz might see if small gains can expand into a broader advantage.
8.49%
10Y net income/share CAGR of 8.49% while CRN.AX is zero. Bruce Berkowitz would see if minor gains can compound into a bigger lead over time.
8.49%
Net income/share CAGR of 8.49% while CRN.AX is zero. Bruce Berkowitz would see if small mid-term gains can develop into a bigger lead.
37.02%
3Y net income/share CAGR of 37.02% while CRN.AX is zero. Bruce Berkowitz sees if minor improvements can widen to a bigger advantage.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-109.42%
Negative 3Y equity/share growth while CRN.AX is at 0.00%. Joel Greenblatt demands an urgent fix in capital structure or profitability vs. the competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.